Page 3 - Peter Greenleaf News Today

Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Rating) (TSE:AUP) had its target price hoisted by Royal Bank of Canada from $11.00 to $13.00 in a research report report published on Tuesday, The Fly reports. Royal Bank of Canada currently has an outperform rating on the biotechnology company’s stock. Separately, StockNews.com assumed coverage on shares of Aurinia Pharmaceuticals […]

Operator: Greetings, and welcome to Aurinia Pharmaceuticals Inc. First Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode.

Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Rating) (TSE:AUP) announced its quarterly earnings data on Thursday. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.05, Briefing.com reports. Aurinia Pharmaceuticals had a negative return on equity of 25.44% and a negative net margin of 80.71%. The firm […]

$34.4 million in net revenue for the first quarter of 2023; an increase of 59% over the first quarter of the prior year Increases 2023 revenue guidance range to $135 - $155 million from net product... | May 4, 2023

$34.4 million in net revenue for the first quarter of 2023; an increase of 59% over the first quarter of the prior year Increases 2023 revenue guidance range to $135 $155 million from net product

Aurinia Pharmaceuticals Inc. today announced that the National Institute for Health and Care Excellence has recommended LUPKYNIS® as an option for treating adults with active lupus nephritis ... | May 3, 2023

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the National Institute for Health and Care Excellence (NICE) has recommended LUPKYNIS (voclosporin) as an option

03.05.2023 - Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the National Institute for Health and Care Excellence (NICE) has recommended LUPKYNIS (voclosporin) as an option for treating adults with active lupus ... Seite 1

Aurinia Pharmaceuticals Inc. today announced that the Swiss Agency for Therapeutic Products has granted marketing authorization of LUPKYNIS® in combination with a background immunosuppressive... | May 2, 2023

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Get Rating) (TSE:AUP) has been assigned an average rating of “Moderate Buy” from the six research firms that are presently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month […]